Navindra Persaud

Dr. Navindra Persaud

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2007 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
NPNavindra Persaud
Navindra Persaud
PMPeter McLeod
Peter McLeod
ACAlan Cowey
Alan Cowey

1 June 2019 in Bulletin of the World Health Organization
Verified
Journal Article
Open access
NPNavindra Persaud
Navindra Persaud
MJMaggie Jiang
Maggie Jiang
RSRoha Shaikh
Roha Shaikh
ABAnjli Bali
Anjli Bali
EOEfosa Oronsaye
Efosa Oronsaye
CHCarl Heneghan
Carl Heneghan
To compare the medicines included in national essential medicines lists with the World Health Organization's (WHO's) Model list of essential medicines, and assess the extent to which countries' characteristics, such as WHO region, size and health care expenditure, account for the differences. We searched the WHO's Essential Medicines and Health Products Information Portal for national essential medicines lists. We compared each national list of essential medicines with both the 2017 WHO model list and other national lists. We used linear regression to determine whether differences were dependent on WHO Region, population size, life expectancy, infant mortality, gross domestic product and health-care expenditure. We identified 137 national lists of essential medicines that collectively included 2068 unique medicines. Each national list contained between 44 and 983 medicines (median 310: interquartile range, IQR: 269 to 422). The number of differences between each country's essential medicines list and WHO's model list ranged from 93 to 815 (median: 296; IQR: 265 to 381). Linear regression showed that only WHO region and health-care expenditure were significantly associated with the number of differences (adjusted R2 : 0.33; P < 0.05). Most medicines (1248; 60%) were listed by no more than 10% (14) of countries. The substantial differences between national lists of essential medicines are only partly explained by differences in country characteristics and thus may not be related to different priority needs. This information helps to identify opportunities to improve essential medicines lists.

15 October 2012 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
NPNavindra Persaud
Navindra Persaud
ECEmily Coleman
Emily Coleman
DZDorothy Zwolakowski
Dorothy Zwolakowski
BLBert Lauwers
Bert Lauwers
DCDan Cass
Dan Cass
Background: The effectiveness of helmets at preventing cycling fatalities, a leading cause of death among young adults worldwide, is controversial, and safety regulations for cycling vary by jurisdiction. We sought to determine whether nonuse of helmets is associated with an increased risk of fatal head injury. Methods: We used a case–control design involving 129 fatalities using data from a coroner’s review of cycling deaths in Ontario, Canada, between 2006 and 2010. We defined cases as cyclists who died as a result of head injuries; we defined controls as cyclists who died as a result of other injuries. The exposure variable was nonuse of a bicycle helmet. Results: Not wearing a helmet while cycling was associated with an increased risk of dying as a result of sustaining a head injury (adjusted odds ratio [OR] 3.1, 95% confidence interval [CI] 1.3–7.3). We saw the same relationship when we excluded people younger than 18 years from the analysis (adjusted OR 3.5, 95% CI 1.4–8.5) and when we used a more stringent case definition (i.e., only a head injury with no other substantial injuries; adjusted OR 3.6, 95% CI 1.2–10.2). Interpretation: Not wearing a helmet while cycling is associated with an increased risk of sustaining a fatal head injury. Policy changes and educational programs that increase the use of helmets while cycling may prevent deaths.

1 January 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
NPNavindra Persaud
Navindra Persaud
MBMichael Bedard
Michael Bedard
ABAndrew S. Boozary
Andrew S. Boozary
RGRichard H. Glazier
Richard H. Glazier
TGTara Gomes
Tara Gomes
FTfor the Carefully Selected and Easily Accessible at No Charge Medicines (CLEAN Meds) Study Team
for the Carefully Selected and Easily Accessible at No Charge Medicines (CLEAN Meds) Study Team
Lifesaving medicines such as treatments for cardiovascular disease and HIV and AIDS are often not accessible because of the cost to patients, among other reasons.1 Global estimates of medication nonadherence are between 40% and 60% for treatments for chronic diseases.2 A systematic review of interventions to improve adherence identified few effective interventions and underscored the need for additional high-quality studies.3 Providing certain medicines at no charge for people with specific conditions such as myocardial infarction, hypertension, HIV and AIDS, and schizophrenia can improve surrogate and direct health measures related to those conditions.4-7 The World Health Organization recommends that countries develop a list of essential medicines “that satisfy the priority health care needs of the population” for the purpose of increasing access and quality of care, and facilitating medicine access is one way to help achieve universal health coverage.8

28 February 2017 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
Aisha LoftersAisha Lofters
Aisha Lofters
ASA. Schuler
A. Schuler
MSM. Slater
M. Slater
Nancy Noel BaxterNancy Noel Baxter
Nancy Noel Baxter
NPNavindra Persaud
Navindra Persaud
TKT. Kiran
T. Kiran
Data on the social determinants of health can help primary care practices target improvement efforts, yet relevant data are rarely available. Our family practice located in Toronto, Ontario routinely collects patient-level sociodemographic data via a pilot-tested survey developed by a multi-organizational steering committee. We sought to use these data to assess the relationship between the social determinants and colorectal, cervical and breast cancer screening, and to describe the opportunities and challenges of using data on social determinants from a self-administered patient survey. Patients of the family practice eligible for at least one of the three cancer screening types, based on age and screening guidelines as of June 30, 2015 and who had answered at least one question on a socio-demographic survey were included in the study. We linked self-reported data from the sociodemographic survey conducted in the waiting room with patients’ electronic medical record data and cancer screening records. We created an individual-level income variable (low-income cut-off) that defined a poverty threshold and took household size into account. The sociodemographic characteristics of patients who were overdue for screening were compared to those who were up-to-date for screening for each cancer type using chi-squared tests. We analysed data for 5766 patients for whom we had survey data. Survey participants had significantly higher screening rates (72.9, 78.7, 74.4% for colorectal, cervical and breast cancer screening respectively) than the 13, 036 patients for whom we did not have survey data (59.2, 65.3, 58.9% respectively). Foreign-born patients were significantly more likely to be up-to-date on colorectal screening than their Canadian-born peers but showed no significant differences in breast or cervical cancer screening. We found a significant association between the low-income cut-off variable and cancer screening; neighbourhood income quintile was not significantly associated with cancer screening. Housing status was also significantly associated with colorectal, cervical and breast cancer screening. There was a large amount of missing data for the low-income cut-off variable, approximately 25% across the three cohorts. While we were able to show that neighbourhood income might under-estimate income-related disparities in screening, individual-level income was also the most challenging variable to collect. Future work in this area should target the income disparity in cancer screening and simultaneously explore how best to collect measures of poverty.

1 October 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
IAItunuoluwa Adekoya
Itunuoluwa Adekoya
DMDarshanand Maraj
Darshanand Maraj
LSLiane Steiner
Liane Steiner
HYHannah Yaphe
Hannah Yaphe
LMLorenzo Moja
Lorenzo Moja
NPNavindra Persaud
Navindra Persaud